Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Feature
  • Published:

Hybritech: Portrait of a Monoclonal Specialist

Bio/Technology volume 1, pages 156–161 (1983)Cite this article

Commercialization of monoclonal antibodies may be the biotechnology success story of the 1980s. While most products of genetic engineering are still characterized as having potential or hypothetical commercial applications, there are at least 30 monoclonal antibody-based products on the market now. Hybritech, a California biotechnology firm, leads the field in production and marketing of new applications for monoclonal antibodies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Authors
  1. Lawrence Prescott
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Prescott, L. Hybritech: Portrait of a Monoclonal Specialist. Nat Biotechnol 1, 156–161 (1983). https://doi.org/10.1038/nbt0483-156

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0483-156

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing